Lantern Pharma Secures EU Patent for AI-Designed Cancer Drug LP-284
July 21st, 2025 1:45 PM
By: Newsworthy Staff
Lantern Pharma's LP-284, an AI-designed drug for non-Hodgkin’s lymphoma, gains EU patent approval, enhancing its global market potential and supporting ongoing clinical trials.
Lantern Pharma (NASDAQ: LTRN) has achieved a significant milestone with the European Patent Office issuing a notice of allowance for a composition of matter patent for LP-284, its clinical-stage drug candidate aimed at treating relapsed or refractory non-Hodgkin’s lymphoma. This patent, which is expected to provide exclusivity through 2039, complements existing intellectual property protections in the U.S. and Japan, facilitating the drug's global commercialization. Developed using Lantern’s innovative RADR(R) AI platform, LP-284 is currently undergoing Phase 1 clinical trials and has been granted Orphan Drug Designations for mantle cell lymphoma (MCL) and high-grade B-cell lymphoma (HGBL). Targeting a $4 billion global market, LP-284's development underscores Lantern Pharma's commitment to leveraging AI for accelerating oncology drug discovery and development, offering a promising avenue for strategic partnerships.
Source Statement
This news article relied primarily on a press release disributed by InvestorBrandNetwork (IBN). You can read the source press release here,
